Human trial of Ebola vaccine will begin next week

The GlaxoSmithkline has fast-tracked an experimental Ebola vaccine. The firm intended to manufacture a stockpile of nearly 10,000 doses for emergency usage.

The experts struggled hard to develop a drug that can help to curb the worst outbreak of Ebola disease. The disease has almost killed 1,500 people in West Africa. An International group provided funds for the research work related to Ebola disease.

United National Institutes of Health (NIH) co-developed this vaccine with GSK. Foremost, the experts will give this vaccine to healthy volunteer of Britain and United States from the month of September. Afterwards, the program will be stretched out to other countries such as the Gambia and Mali.

The GlaxoSmith said on Thursday that stage 1 experiment would begin soon after the approval of ethical and regulatory.

Currently, the NIH’s National Institute of Allergy and Infectious Disease is working on an extensive program of medical trials. These trials comprise of test of a GSK version which may help in struggling with the second type of Ebola.

Moreover, U.S researchers plan a human test of vaccine that is discovered by the scientist of Canadian government.

Experts will uncover whether this vaccine is safe or trigger an immune response through the healthy volunteers of experiment.

The chief goal of researchers is to accomplish this task till the end of year 2014.

Bio
Latest Posts

Karen Jackson

Karen Jackson has always been passionate about technology. All the way through high-school she immersed herself in computers and web-design. Her ambitious nature helped her become a pro in Adobe Photoshop only by watching online videos and working with the program herself. This is also the program that she mostly uses in the creation of websites at her work-place. Technological innovation and gadgets that push the boundaries of what we are comfortable with have always fascinated her, so expect to see some weird gadget reviews coming from her.